Indegene, a healthcare information technology (IT) firm that assists global healthcare organisations address complex challenges by integrating analytics, technology, operations and medical expertise, has bought Canada’s Skura Corporationâs life science business for $9 million (about Rs 60 crore) to expand its technology offerings to life sciences and pharmaceutical companies.
Indegene, on April 29, announced the acquisition of Skura Corporationâs life science business. Skura Corporationâs SFX platform is a global leader in adaptive sales-enablement technology for life science organisations and delivers next-generation sales-enablement technology, ensuring the right message reaches the right healthcare providers (HCPs) at the right time, thus, increasing sales and customer success.
Backed by Infosysâ cofounder NS Raghavan,Â the Skura Corporation acquisition is the latest in a string of deals for Indegene, which is targeting $250 million in revenue by 2020 and considering an initial public offering on NASDAQ. In 2012, it acquired Aptillon for $4 million and in 2014 it acquired outcome research and clinical engagement services company Total Therapeutics.